# Renaissance

> Renaissance is a VC fund in Lausanne backing Medical, Software and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Lausanne, Switzerland
- Total investments: 7
- Last investment: Jun 2017
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/renaissance-foundation-&-management
- Website: http://renaissance.net

Renaissance is an investment foundation for pension funds investing in Swiss SMEs. It acts as a partner of the SMEs, participating in companies within the framework of succession planning or company outsourcing and thus promotes the Swiss SME landscape by maintaining and creating jobs.The firm was founded in 1997 and is headquartered in Lausanne,Vaud.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $17M–$36M |
| Series C | $5.8M–$29M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 29% |
| Software | 2 | 29% |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| SaaS | 1 | 14% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series C | 2 | 29% |
| Seed | 1 | 14% |
| Series A | 1 | 14% |
| Convertible Note | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GlassIG | It is an independent software vendor. Our aim is to provide market leading and cost effective Information Governance for everyone. At They are proud of our mission to serve and inspire our customers to establish and operate an effective Information Governance solution. | $2.7M | Seed | Jun 07, 2017 |  |
| Anergis | Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland. | $5.8M | Series C | Apr 04, 2016 |  |
| Anergis | Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland. | $16.9M | Series B | Dec 03, 2014 |  |
| beqom | Happiness is the best driver for success.Their mission is to make the workforce of their customers happy. beqom drives happiness by allowing business managers to lead, align and motivate employees and partners. The beqom Total Compensation platform is used globally across all industry sectors by over 100 large companies such as Microsoft andVodafone. It addresses all Performance and Compensation aspects such as Salary Review, Bonus, Long-Term Incentives, Commissions, Benefits, Non-cash rewards and all key drivers towards Employee Performance and Sales Performance. HR, Sales and Finance organizations leverage their platform to drive performance, retention, cost optimization and... happiness among their people.beqom – to make your people happy. | $10.6M | Convertible Note | Apr 01, 2014 |  |
| Anergis | Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland. | $9.3M | Series A | Feb 07, 2014 |  |
| Addex Therapeutics | Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and mayoffer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. | $29.4M | Series C | Sep 19, 2006 |  |
| Addex Therapeutics | Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and mayoffer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. | $36.2M | Series B | May 17, 2004 |  |

7 of 7 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 3 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 3 deals together
- [VINCI CAPITAL](https://shizune.co/investors/profile/vinci-capital) — VC Fund, 3 deals together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 2 deals together
- [Index Ventures](https://shizune.co/investors/profile/index-ventures) — VC Fund, 2 deals together
- [PolyTechnos Venture Partners](https://shizune.co/investors/profile/polytechnos-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Enterprise Software Investors in Switzerland](https://shizune.co/investors/enterprise-software-investors-switzerland)
- [Enterprise Software VC Funds in Switzerland](https://shizune.co/investors/enterprise-software-vc-funds-switzerland)
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)

## FAQ

### What does Renaissance invest in?

Renaissance invests primarily in Medical, Software and Health Care startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Renaissance's check size?

Renaissance typically joins rounds of $17M–$36M at Series B and $5.8M–$29M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Renaissance participates in.

### When did Renaissance last invest?

The most recent investment recorded for Renaissance closed in Jun 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co